Apr 27, 2022 / 05:30PM GMT
Mayank Mamtani - B. Riley Securities, Inc. - Analyst
Good afternoon and good morning to folks there on the West Coast. Welcome back to our next company presentation with Cassava Sciences -- I should say fireside chat actually -- with President and CEO, Remi Barbier; and Chief Financial Officer, Eric Schoen. Thank you both for joining us and being part of the conference. Appreciate you making time in your busy schedules.
Questions and Answers:
Mayank Mamtani - B. Riley Securities, Inc. - AnalystSo just to be frank, I'd be a little surprised if people were unaware of what's going on with Cassava, but I think if you could just maybe start at a high level, talking about Cassava's lead drug simufilam, some of your preclinical, clinical activity over the years, and sort of the potential in Alzheimer's disease.
Remi Barbier - Cassava Sciences, Inc. - President & CEO
Sure, Mayank. Great way to kick off the conference, and thank you for inviting us. Before we talk, we're a public company, so I need to go through a
Trustpilot
